IC
Ikarian Capital Portfolio holdings
AUM
$494M
1-Year Est. Return
153.64%
1 Year Est. Return
+153.64%
AUM
$494M
AUM Growth
+$192M
(+64%)
Holding
157
Top Buys
| 1 | +$53M | |
| 2 | +$33.4M | |
| 3 | +$27.2M | |
| 4 |
PTC Therapeutics
PTCT
|
+$17.2M |
| 5 |
RAPT Therapeutics
RAPT
|
+$15.9M |
Top Sells
| 1 | +$21.6M | |
| 2 | +$18.5M | |
| 3 | +$17.9M | |
| 4 |
Cogent Biosciences
COGT
|
+$14.7M |
| 5 |
VRNA
Verona Pharma
VRNA
|
+$13.9M |
Sector Composition
| 1 | Healthcare | 99.25% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
151
Novo Nordisk
NVO
$277B
| – | – |
0
|
|
||
152
Prothena Corp
PRTA
$503M
| – | – |
0
|
|
||
153
Ultragenyx Pharmaceutical
RARE
$2.17B
| – | – |
0
|
|
||
154
Arcus Biosciences
RCUS
$2.7B
| – | – |
-163,363
|
|
||
155
Revolution Medicines
RVMD
$23.3B
| – | – |
0
|
|
||
156
Sagimet Biosciences
SGMT
$200M
| – | – |
-11,984
|
|
||
157
Sarepta Therapeutics
SRPT
$2.21B
| – | – |
-449,087
|
|